Welcome to our dedicated page for ACHIKO NAMEN AKT news (Ticker: ACHKF), a resource for investors and traders seeking the latest updates and insights on ACHIKO NAMEN AKT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACHIKO NAMEN AKT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACHIKO NAMEN AKT's position in the market.
Achiko AG (OTCQB: ACHKF) reported its 2021 financial results, showing a net loss of USD $9,231,779, increasing accumulated losses to USD $34,568,395. The Group's assets were negative $4.584 million, yet it holds $2.4 million in subordinated loans. An adverse audit opinion highlighted the company's reliance on a successful capital increase and creditor support to continue operations. Despite challenges, the AptameX™ Covid-19 test demonstrated a >97% sensitivity and specificity. A large sales deal for 1 million tests was secured with Nahdlatul Ulama, and CE Mark approval was achieved for commercial efforts in the EU.
Achiko AG, listed on SIX, announced the publication of its annual report and financial statements for 2021 by June 26, 2022. Delays were attributed to COVID-19 impacts and increased administrative workload. The company requested multiple extensions from SIX Exchange Regulation, which were granted, emphasizing the need for timely communication regarding operational continuity. The CEO's COVID-19 infection further impeded progress. Achiko is focused on developing diagnostic solutions, including a rapid COVID-19 test and related app, with future regulatory submissions planned for Europe.
Achiko AG has announced that it will publish its annual report and financial statements for 2021 by June 20, 2022, following multiple extension requests granted by SIX Exchange Regulation. The delays are attributed to challenges from the Covid-19 pandemic and increased administrative workload. Preliminary financial figures reveal a significant revenue drop from $2.8 million in 2020 to $63,000 in 2021, with an EBITDA loss of $8.3 million. The company focuses on commercializing its Covid-19 test AptameX and has made progress, including securing financing and key agreements in Indonesia.
Achiko AG (SIX: ACHI; OTCQB: ACHKF) announced a delay in publishing its annual report and financial statements for 2021. The new deadline is set for June 10, 2022, due to challenges such as the Covid-19 pandemic and increased administrative workload. Achiko has received several extensions from SIX Exchange Regulation (SER) for this publication. Failure to meet the new deadline may lead to trading suspension of its shares. The company is involved in developing Covid-19 diagnostic solutions and aims to submit an application for CE Mark approval in Europe in 2022.
Achiko AG (OTCQB: ACHKF; SIX: ACHI) has announced the delayed publication of its 2021 annual report and financial statements, now due on June 6, 2022. This extension was requested and granted by SIX Exchange Regulation due to challenges posed by the COVID-19 pandemic, including staffing and training issues. Achiko does not anticipate significant changes from the previously released unaudited figures. The upcoming annual general meeting is scheduled for June 27, 2022, and the company focuses on developing innovative diagnostic solutions, including a COVID-19 test and health app.
Achiko AG announces a USD$1.3 million financing with strategic investors Buranto AG and Negma Group, aiming to enhance production capabilities for AptameX™. Buranto AG provided a USD$260,000 loan and Derek Brandt will join Achiko’s Advisory Board. Negma Group contributed USD$1.04 million, of which USD$520,000 is immediately available. The funds will facilitate production in Indonesia and Taiwan following the recent CE mark approval for AptameX™.
Achiko AG (SIX: ACHI; OTCQB: ACHKF) reported a full-year adjusted EBITDA loss of USD$5,272,179 for 2021, a reduction from USD$8,728,709 in 2020. The company's revenue plummeted to USD$60,014, down from USD$2,805,708 the previous year, reflecting a significant transition phase. Shareholders’ equity slightly decreased to USD ($4,297,969). Notably, the restructuring of European operations led to reduced operating costs and improved performance in the latter half of the year. The company anticipates a significant decline in share-based compensation moving forward.
Achiko AG has successfully registered AptameX™ and obtained a CE Mark, enabling the sale of its COVID-19 test across 27 EU countries. This marks the first significant application of DNA aptamers in consumer testing. AptameX demonstrates over 97% sensitivity and specificity, surpassing many rapid tests. The company aims for widespread commercial availability by Q3 2022, backed by production initiatives in Indonesia and contract manufacturing in Taiwan.
With AptameX, Achiko seeks to address challenges in COVID-19 testing as the virus becomes endemic.
Achiko AG (SIX: ACHI; OTCQB: ACHKF) announced an extension for publishing its annual report and financial statements for 2021, now due by May 31, 2022. This delay was attributed to challenges arising from the Covid-19 pandemic and staffing changes. The SIX Exchange Regulation granted the exemption, warning that failure to meet this deadline could lead to trading suspension. The company’s annual general meeting is also postponed to late June 2022. Achiko continues to focus on its Covid-19 diagnostic solutions and is set to seek CE Mark approval in 2022.
Achiko AG has initiated shipping of its AptameX Covid-19 rapid test kits, expecting first sales in May 2022. The company has reorganized its production line in Indonesia to cater to stronger than anticipated demand, with plans for over two million kits. AptameX demonstrates over 97% sensitivity and specificity against PCR tests. Future financing will be supported by working capital and trade finance options as Achiko aims for international expansion post-CE Mark approval.
FAQ
What is the market cap of ACHIKO NAMEN AKT (ACHKF)?
